Drug Trial Radar · NCT02773030
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
466
Actual
Start
Oct 14, 2016
Primary completion
May 9, 2024
Study completion Jul 28, 2028
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 16, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.
Conditions
- Multiple Myeloma
Interventions
CC-220Drug
CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
DexamethasoneDrug
Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
DaratumumabDrug
Specified dose on specified days
BortezomibDrug
Specified dose on specified days
CarfilzomibDrug
Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1 and C1D2; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle.
Daratumumab - 16mg/kgDrug
Daratumumab (DARA) 16mg/kg by intravenous infusion on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.
Bortezomib (BTZ)Drug
Bortezomib 1.3 mg/m\^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.
Daratumumab- 1800mgDrug
Daratumumab (DARA) 1800 mg by subcutaneous injection on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities in Part 1.Time frame: From first dose to 28 days post last dose (up to 28 days)
- Overall Response Rate (ORR) in Cohort D and Cohort H2Time frame: Approximately on average (Cohort D: 21.14 weeks, Cohort H2: 22.11 Weeks)
Locations
162 sites in 11 countries. Site status is shown where the registry gives one.
Local Institution - 102
Scottsdale, Arizona
Mayo Clinic
Scottsdale, Arizona
Local Institution - 107
Little Rock, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Local Institution - 101
Atlanta, Georgia
Winship Cancer Institute of Emory University
Atlanta, Georgia
Local Institution - 120
Chicago, Illinois
Robert H Lurie Comprehensive Cancer Center NW Univ
Chicago, Illinois
Local Institution - 113
Fairway, Kansas
University of Kansas Cancer Center
Fairway, Kansas
Local Institution - 106
Baltimore, Maryland
University of Maryland School of Med
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Local Institution - 114
Boston, Massachusetts
Local Institution - 115
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber/Mass General Brigham Cancer Care, Inc
Boston, Massachusetts
Local Institution - 110
Boston, Massachusetts
Local Institution - 104
Ann Arbor, Michigan
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Local Institution - 103
Detroit, Michigan
Local Institution - 140
Grand Island, Nebraska
Local Institution - 141
Grand Island, Nebraska
Local Institution - 137
Omaha, Nebraska
Local Institution - 138
Omaha, Nebraska
Local Institution - 131
Omaha, Nebraska
Local Institution - 139
Papillion, Nebraska
Local Institution - 756
Cherry Hill, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey
Local Institution - 108
Hackensack, New Jersey
Local Institution - 122
Mineola, New York
NYU Winthrop Hospital
Mineola, New York
Local Institution - 121
New York, New York
New York University School of Medicine
New York, New York
Icahn School of Medicine at Mount Sinai Medical Center
New York, New York
Local Institution - 109
New York, New York
Local Institution - 111
New York, New York
New York Presbyterian Hospital Weil Cornell Medical College
New York, New York
Local Institution - 125
Rochester, New York
Showing 40 of 162 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.